Effect of probiotic yoghurt (L. plantarum strain TENSIA) on healthy volunteers
ISRCTN | ISRCTN31663396 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN31663396 |
Secondary identifying numbers | 200-T4 from 17/01/2010 |
- Submission date
- 24/01/2011
- Registration date
- 21/06/2011
- Last edited
- 07/02/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Marika MIkelsaar
Scientific
Scientific
Ravila 19
Tartu
50411
Estonia
marika.mikelsaar@ut.ee |
Study information
Study design | Randomised double-blind cross-over intervention study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | GP practice |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Effect of probiotic yoghurt comprising L. plantarum strain TENSIA on blood indices and intestinal microflora of healthy volunteers: A randomised controlled crossover trial |
Study acronym | JOG3 |
Study objectives | The consumption of yoghurt containing probiotic L. plantarum strain TENSIA has positive impact on blood indices of healthy volunteers. |
Ethics approval(s) | Ethics Review Committee on Human Research of the University of Tartu approved on the 17th January 2010 (ref: 200-T4) |
Health condition(s) or problem(s) studied | Blood indices, intestinal microflora |
Intervention | The consumption once a day 150 g of probiotic yoghurt versus regular yoghurt for 3 weeks. Probiotic yoghurt containing either Lactobacillus plantarum strain TENSIA (10^9 colony forming units [CFU]/g). After two-week washout period, volunteers are crossed over to another three weeks of probiotic yoghurt or control yoghurt administration. Fasting blood samples are collected. |
Intervention type | Other |
Primary outcome measure | 1. The health indices of study participants (height, weight, body mass index, blood pressure) assessed at the recruitment, after 3 weeks of probiotic treatment, after washout and after 3-week placebo treatment 2. The self-reported questionnaire containing questions on welfare, and habitual gastrointestinal symptoms (abdominal pain, flatulence, bloating, and stool frequency), measured once a week during the trial 3. Haematological indices (haemoglobin, white blood cell count, red blood cells, platelets), plasma glucose, albumin, total cholesterol, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides, high sensitivity C reactive protein (hs-CRP) and interlukin (IL)-6 measured at the recruitment, after 3 weeks of probiotic treatment, after washout and after 3-week placebo treatment |
Secondary outcome measures | Circulation of polyamines in host, oxidised low density lipoprotein (oxLDL), 8-isoprostanes, adiponectine, leptin, cytokines and growth factors (IL1 alfa, IL1beta, IL2, IL4, IL6, IL8, IL10, VEGF, EDG, ITFgamma, TNFalfa, MCP-1), osteoprotegerin |
Overall study start date | 07/02/2011 |
Completion date | 04/04/2011 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 100 persons of both sexes, divided into in two groups |
Key inclusion criteria | 1. Wish to participate in the study 2. Aged 18 years and over, either sex 3. Healthy (i.e. no known health problems and no medical conditions that require drug therapy) 4. Signed informed consent |
Key exclusion criteria | 1. History of any gastrointestinal disease 2. Use of any antimicrobial drug within last month 3. Use of any regular concomitant medication, including medical preparations 4. Food allergy 5. Pregnancy or breastfeeding |
Date of first enrolment | 07/02/2011 |
Date of final enrolment | 04/04/2011 |
Locations
Countries of recruitment
- Estonia
Study participating centre
Ravila 19
Tartu
50411
Estonia
50411
Estonia
Sponsor information
BioCC OÜ
Hospital/treatment centre
Hospital/treatment centre
Kreutzwaldi 1
Tartu
51014
Estonia
Phone | +372 (0)731 3411 |
---|---|
ene.tammsaar@tptak.ee | |
Website | http://www.tptak.ee |
Funders
Funder type
Industry
Bio-Competence Centre of Healthy Dairy Products LLC (Estonia)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan | Not provided at time of registration |
Editorial Notes
07/02/2022: The sponsor organisation has been changed from "Bio-Competence Centre of Healthy Dairy Products LLC (Estonia)" to "BioCC OÜ".